Highlights Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/04/2026 BST			5-day change	1st Jan Change
21.17 ^USD	+0.43%		+16.57%	-2.62%

04-16	Eqt X Usd Scsp and Eqt X Eur Scsp, managed by Eqt Fund Management S.à R.L cancelled the acquisition of Intertek Group plc for £8.1 billion.	CI
04-14	Genscript Biotech Associate Logs $597 Million in Q1 Sales of Carvykti	MT

Highlights

04-16	Eqt X Usd Scsp and Eqt X Eur Scsp, managed by Eqt Fund Management S.à R.L cancelled the acquisition of Intertek Group plc for £8.1 billion.	CI
03-10	Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-10	Legend Biotech Adjusted Q4 Earnings, Revenue Increase	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q4 Revenue $306.3M, vs. FactSet Est of $307.8M	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q4 Adjusted Net Income $0.01 per Share	MT
03-10	Earnings Flash (LEGN) Legend Biotech Posts Q4 Loss $0.08 a Share, vs. FactSet Est of $0.02 EPS	MT
02-23	Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion	RE
12-08	Legend Biotech Corporation Highlights New CARVYKTI Data in Multiple Myeloma and First-In-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma	CI
11-13	Legend Biotech Corporation Celebrates Official Opening of New Cell Therapy Research and Development Facility in Philadelphia	CI
11-12	Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	Legend Biotech Q3 Adjusted Loss Narrows, Revenue Rises	MT
11-12	Legend Biotech Q3 revenue slightly misses estimates	RE
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q3 Revenue $272.3M, vs. FactSet Est of $274.4M	MT
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q3 Adjusted Loss $0.05 per Share	MT
15/10/25	GenScript Associate Books $524 Million in Q3 CARVYKTI Sales	MT
14/10/25	Legend Biotech Corporation Announces U.S. Fda Approves Label Updates for Carvykti® Car-T Cell Therapy to Include Overall Survival Data	CI
13/10/25	The Presidential Whiplash Index
07/10/25	Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc	CI
05/09/25	Legend Biotech Said to Consider Second Listing Outside US	MT
05/09/25	Legend Biotech Said to Consider Second Listing Outside US, Bloomberg Reports	MT
11/08/25	Legend Biotech Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/08/25	Correction: Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Adjusted EPS $0.03 per Share	MT
11/08/25	Legend Biotech Swings to Q2 Adjusted Earnings, Revenue Rises	MT
11/08/25	Legend Biotech Q2 collaboration revenue up on CARVYKTI sales	RE
11/08/25	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q2 Revenue $255.1M, vs. FactSet Est of $228.0M	MT